Clinical profiles, treatment adherence, and quality of life in patients with severe mental disorders treated with cyamemazine: A real-world observational study.

IF 1 4区医学 Q4 NEUROSCIENCES

Encephale-Revue De Psychiatrie Clinique Biologique et Therapeutique Pub Date : 2025-03-15 DOI:10.1016/j.encep.2025.01.003

Mélanie Faugère, Vincent Achour, Eloïse Maakaron, Pierre Verney, Jade Obadia, Christelle Andrieu-Haller, Antoine Lefrere, Michel Cermolacce, Guillaume Fond, Christophe Lançon, Théo Korchia

{"title":"Clinical profiles, treatment adherence, and quality of life in patients with severe mental disorders treated with cyamemazine: A real-world observational study.","authors":"Mélanie Faugère, Vincent Achour, Eloïse Maakaron, Pierre Verney, Jade Obadia, Christelle Andrieu-Haller, Antoine Lefrere, Michel Cermolacce, Guillaume Fond, Christophe Lançon, Théo Korchia","doi":"10.1016/j.encep.2025.01.003","DOIUrl":null,"url":null,"abstract":"Background: Cyamemazine, a phenothiazine antipsychotic with anxiolytic and sedative properties, is commonly used in the management of severe mental disorders (SMDs) such as schizophrenia, bipolar disorder, and major depressive disorder. Despite its unique pharmacological profile, the impact of cyamemazine on clinical outcomes, treatment adherence, and quality of life (QoL) remains inadequately studied. This study addresses the significant gap in understanding the clinical impact of cyamemazine, a widely used yet under-researched antipsychotic.Methods: This observational study was conducted at a university psychiatry unit in Marseille, France, involving patients with SMDs. Sociodemographic, clinical, and comorbid characteristics were assessed, along with treatment adherence, QoL, and side effects using validated instruments including the Medication Adherence Rating Scale (MARS) and the Schizophrenia Quality of Life Scale (SQoL-18). Multivariate analyses were performed to explore the associations between cyamemazine use and clinical outcomes.Results: A total of 1,248 patients were included with 55 (4.4%) using cyamemazine. Cyamemazine users presented more severe clinical profiles, with higher anxiety, more hospitalizations, and poorer functioning. Although cyamemazine's anxiolytic effects may improve adherence, its sedative and metabolic side effects were associated with reduced QoL and functional impairment.Conclusions: The study highlights the need for personalized treatment strategies that weigh the benefits of cyamemazine against its potential risks. Integrating pharmacological and non-pharmacological interventions could enhance patient outcomes.","PeriodicalId":51042,"journal":{"name":"Encephale-Revue De Psychiatrie Clinique Biologique et Therapeutique","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Encephale-Revue De Psychiatrie Clinique Biologique et Therapeutique","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.encep.2025.01.003","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cyamemazine, a phenothiazine antipsychotic with anxiolytic and sedative properties, is commonly used in the management of severe mental disorders (SMDs) such as schizophrenia, bipolar disorder, and major depressive disorder. Despite its unique pharmacological profile, the impact of cyamemazine on clinical outcomes, treatment adherence, and quality of life (QoL) remains inadequately studied. This study addresses the significant gap in understanding the clinical impact of cyamemazine, a widely used yet under-researched antipsychotic.

Methods: This observational study was conducted at a university psychiatry unit in Marseille, France, involving patients with SMDs. Sociodemographic, clinical, and comorbid characteristics were assessed, along with treatment adherence, QoL, and side effects using validated instruments including the Medication Adherence Rating Scale (MARS) and the Schizophrenia Quality of Life Scale (SQoL-18). Multivariate analyses were performed to explore the associations between cyamemazine use and clinical outcomes.

Results: A total of 1,248 patients were included with 55 (4.4%) using cyamemazine. Cyamemazine users presented more severe clinical profiles, with higher anxiety, more hospitalizations, and poorer functioning. Although cyamemazine's anxiolytic effects may improve adherence, its sedative and metabolic side effects were associated with reduced QoL and functional impairment.

Conclusions: The study highlights the need for personalized treatment strategies that weigh the benefits of cyamemazine against its potential risks. Integrating pharmacological and non-pharmacological interventions could enhance patient outcomes.

查看原文本刊更多论文

cyamemazine治疗严重精神障碍患者的临床概况、治疗依从性和生活质量：一项真实世界的观察性研究

背景：Cyamemazine是一种具有抗焦虑和镇静作用的吩噻嗪类抗精神病药物，常用于治疗严重精神障碍（SMDs），如精神分裂症、双相情感障碍和重度抑郁症。尽管其独特的药理学特征，氰胺嗪对临床结果、治疗依从性和生活质量（QoL）的影响仍未充分研究。本研究解决了在了解cyamemazine的临床影响方面的重大差距，cyamemazine是一种广泛使用但研究不足的抗精神病药。方法：这项观察性研究在法国马赛的一所大学精神病学部门进行，涉及smd患者。使用包括药物依从性评定量表（MARS）和精神分裂症生活质量量表（SQoL-18）在内的有效工具评估社会人口学、临床和合并症特征，以及治疗依从性、生活质量和副作用。进行多变量分析以探讨氰胺嗪使用与临床结果之间的关系。结果：共纳入1248例患者，其中55例（4.4%）使用氰胺嗪。Cyamemazine使用者表现出更严重的临床特征，有更高的焦虑，更多的住院治疗和更差的功能。虽然氰胺嗪的抗焦虑作用可以改善依从性，但其镇静和代谢副作用与生活质量降低和功能损害有关。结论：该研究强调了个性化治疗策略的必要性，权衡cyamemazine的益处和潜在风险。结合药物和非药物干预可以提高患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Encephale-Revue De Psychiatrie Clinique Biologique et Therapeutique 医学-精神病学

CiteScore

4.60

自引率

7.40%

发文量

162

审稿时长

6-12 weeks

期刊介绍： Une revue française de renommée internationale. - Un comite de rédaction représentant tous les aspects de la prise en charge psychiatrique du patient. - Une sélection rigoureuse d''articles faisant l''objet de plusieurs expertises. - Des travaux d''auteurs et de chercheurs de renommée internationale. - Des indexations dans les grandes bases de données (Current Contents, Excerpta Medica, etc.). - Un facteur d''impact qui témoigne de la grande notoriété de la revue. La tribune des publications originales de haut niveau. - Une très grande diversité des sujets traités, rigoureusement sélectionnés à travers des sommaires dynamiques : - des éditoriaux de médecins référents, - une revue de presse sur les actualités internationales, - des articles originaux pour approfondir vos connaissances, - des mises au point et des cas cliniques pour engager votre réflexion sur les indications et choix possibles au travers de mises en situation clinique, - des dossiers thématiques pour faire le tour d''une question. - L''actualité de l''AFPB : L''Encéphale publie régulièrement des comptes rendus de l''Association française de psychiatrie clinique.